Skip to content

← All developments

New York Legislature (healthcare bills) · October 2, 2026 · Primary source

NY A 2126: Establishes a pilot program on upper payment limits for prescription drugs

Score 46PRIMARYregulatoryState legislatureNY

Summary

New York Assembly Bill A2126B establishes a pilot program imposing upper payment limits on prescription drugs in New York, with those limits set at no less than the maximum fair price published by the HHS Secretary under federal drug price negotiation. The bill has been amended and reprinted as A2126B and has not been enacted. It ties New York's state drug price ceiling directly to the CMS negotiated drug price framework.

What this may mean

If enacted, the bill requires that New York prescription drug upper payment limits be pegged at or above the HHS-published maximum fair price, creating a floor linked to the federal Medicare Drug Price Negotiation Program. Payors, PBMs, and state Medicaid managed care organizations operating in New York would be bound by these limits in covered transactions. The pilot program structure limits initial breadth but could expand.

Informational only. Not legal, medical, financial, or other professional advice. Always consult a qualified professional familiar with your specific facts before relying on any item.

Related items